| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Neophytadiene targets various biological pathways through its terpene structure. As a diterpene hydrocarbon, it may interact with cellular membranes and modulate membrane fluidity. Its antimicrobial activity suggests interactions with microbial cell membranes. Its anti-inflammatory activity may involve modulation of inflammatory cytokine production. Its antioxidant properties suggest free radical scavenging activity. Further research is needed to identify its specific molecular targets and mechanisms of action.
|
|---|---|
| ln Vitro |
On RAW 264, neophytadiene has cytotoxic effects.7 cells exhibiting a 50 μM IC50[1]. Induction of NO production and downregulation of iNOS production in RAW264 induced by 1 μg/mL of LPS is effectively achieved by neophytadiene (50-100 μM; 30 min).Seven cells [1]. Neophytadiene (25-100 μM; 22 hours) dramatically reduces the production of NO as well as the inflammatory cytokines TNF-α, IL-6, IL-10, and IL-10 in RAW264 that has been induced by LPS (1 μg/mL).
7 cells [1].
In vitro studies have demonstrated that Neophytadiene exhibits antimicrobial, anti-inflammatory, and antioxidant activities. Its antimicrobial activity has been assessed against various bacterial and fungal strains. Its anti-inflammatory activity has been evaluated in cell-based assays measuring cytokine production. Its antioxidant activity has been assessed using cell-free systems such as DPPH radical scavenging assays. These in vitro findings support its potential applications in natural product research and drug discovery. |
| ln Vivo |
The level of alanine aminotransferase (ALT) decreases in a dose-dependent manner when administered with neophytadiene (50 mg/kg; p.o.; daily; for 7 days)[1]. Neophytadiene (25–50 mg/kg; p.o.; daily; for 7 days) dramatically lowers the levels of IL-6 and 1L-10 that are elevated in heart tissue and in response to LPS (10 mg/kg)[1]. Neophytadiene (25–50 mg/kg; p.o.; daily; for 7 days) dramatically lowers the elevated PGE2 mRNA expression in heart tissue caused by LPS (10 mg/kg)[1]. In vivo, neophytadiene significantly reduces the production of NO and the inflammatory cytokines TNF-α, IL-6, IL-10, and IL-10 induced by LPS (10 mg/kg)[1].
In vivo studies of Neophytadiene are limited as the compound is primarily used as a research chemical. As a diterpene hydrocarbon found in various plants, it may contribute to the pharmacological effects of plant extracts. Its antimicrobial, anti-inflammatory, and antioxidant activities suggest potential for in vivo evaluation in relevant disease models. However, comprehensive in vivo pharmacological studies specifically targeting Neophytadiene are not well documented in the available literature. The compound is intended for research use only. |
| Enzyme Assay |
In vitro enzyme assays for Neophytadiene typically involve testing its antioxidant and anti-inflammatory activities. Antioxidant activity is assessed using cell-free systems such as DPPH radical scavenging assays, ABTS assays, or ferric reducing antioxidant power (FRAP) assays. Anti-inflammatory activity is assessed by measuring inhibition of COX, LOX, or other inflammatory enzymes. Antimicrobial activity is assessed using standard disc diffusion or broth microdilution methods. All assays are performed with appropriate controls and standardized protocols.
|
| Cell Assay |
In vitro cell-based assays for Neophytadiene involve culturing cells to evaluate its anti-inflammatory and antimicrobial activities. For anti-inflammatory studies, immune cells are treated with the compound and stimulated with inflammatory stimuli; cytokine production is measured by ELISA. For antimicrobial studies, bacterial or fungal cultures are treated with the compound and cell viability is monitored. Cell viability is assessed using MTT or similar colorimetric assays. All experiments are performed in triplicate with appropriate controls.
|
| Animal Protocol |
Animal/Disease Models: Adult male Sprague Dawley rats (6-8 weeks)[1]
Doses: 12 mg/kg, 25 mg/kg, 50 mg/kg Route of Administration: Oral administration, daily, for 7 days Experimental Results: diminished haemoglobin (HGB) level, ALT level, and heart tissue TNF-α, IL1β, NF-κB, iNOS, PI3k/AktandMAPK in LPS (10 mg/kg)-treat rats. In vivo animal experiments for Neophytadiene would be conducted to evaluate its antimicrobial, anti-inflammatory, and antioxidant activities. For antimicrobial studies, infected animals would be treated and pathogen load assessed. For anti-inflammatory studies, animals with induced inflammation would be treated and inflammatory markers measured. For antioxidant studies, animals would be administered the compound and markers of oxidative stress measured. Parameters assessed would include body weight, organ weights, and histopathology. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines. |
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Neophytadiene reflect its nature as a diterpene hydrocarbon. It has a molecular formula of C20H38. As a lipophilic hydrocarbon, it would be absorbed through the gastrointestinal tract and distributed to lipid-rich tissues. The compound is expected to be metabolized through standard xenobiotic pathways in the liver. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Neophytadiene has been evaluated in the context of its use as a research chemical. As a naturally occurring diterpene hydrocarbon found in various plants, it is expected to have a favorable safety profile at research concentrations. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile.
|
| References | |
| Additional Infomation |
Neophytadiene is a diterpene with the structure 3-methylenehexadec-1-ene, substituted with methyl groups at positions 7, 11, and 15. It possesses dual activities including anti-inflammatory, antibacterial, and phytometabolic activity. It is both an olefin and a diterpene. Neophytadiene has been reported to exist in scallions (Allium ampeloprasum), Canary seaweed (Cedronella canariensis), and other organisms with relevant data.
Neophytadiene (CAS# 504-96-1) is a diterpene hydrocarbon with the molecular formula C20H38. It is a branched-chain alkene found in various plants and is a component of essential oils. Neophytadiene has been reported to exhibit various biological activities including antimicrobial, anti-inflammatory, and antioxidant properties. The compound is used in research applications for studying terpene chemistry and natural product biology. It is intended for research use only. |
| Molecular Formula |
C20H38
|
|---|---|
| Molecular Weight |
278.52
|
| Exact Mass |
278.297
|
| CAS # |
504-96-1
|
| PubChem CID |
10446
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.796g/cm3
|
| Boiling Point |
344.5ºC at 760mmHg
|
| Flash Point |
160.2ºC
|
| Index of Refraction |
1.449
|
| LogP |
7.167
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
0
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
20
|
| Complexity |
249
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)CCCC(C)CCCC(C)CCCC(=C)C=C
|
| InChi Key |
NIDGCIPAMWNKOA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H38/c1-7-18(4)12-9-14-20(6)16-10-15-19(5)13-8-11-17(2)3/h7,17,19-20H,1,4,8-16H2,2-3,5-6H3
|
| Chemical Name |
7,11,15-trimethyl-3-methylidenehexadec-1-ene
|
| Synonyms |
Neophytadiene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5904 mL | 17.9520 mL | 35.9041 mL | |
| 5 mM | 0.7181 mL | 3.5904 mL | 7.1808 mL | |
| 10 mM | 0.3590 mL | 1.7952 mL | 3.5904 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
